Ascendiant Capital Rates Outlook Therapeutics (OTLK) buy

Ascendiant Capital has reiterated its Buy rating on Outlook Therapeutics, setting a new price target of $10.00, a 796.86% upside from the current price.

By TradeTexts Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ascendiant Capital rated Outlook Therapeutics, Inc. ($OTLK) "buy" with a $10 price target on June 11, 2026.

Since the rating, $OTLK is up 43.6% after 1 week, up 40.9% after 1 month and down 55.5% to date (from the $1.10 close on Jun 11, 2026).

OTLK Outlook Therapeutics, Inc.

$0.49 -25.76% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Ascendiant Capital reiterated its Buy rating on Outlook Therapeutics (OTLK), raising the price target to $10.00 from $10.00.
Ascendiant Capital's $10 price target implies 796.86% upside from Outlook Therapeutics, Inc.'s ($OTLK) current $1.11 share price.
OTLK shares closed at $1.11 on the NasdaqCM, a significant gap from the new target price of $10.00.
The healthcare company, which focuses on ophthalmic treatments, has a market cap of approximately $167 million.

Get $OTLK trade alerts by text

We text you when insiders, Congress or big funds trade $OTLK. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Outlook Therapeutics, Inc. alert may contain errors. Disclosures

Ascendiant Capital Maintains Positive Outlook

On June 11, 2026, Ascendiant Capital reiterated its Buy rating on Outlook Therapeutics, Inc. (OTLK) and set a price target of $10.00. This target reflects continued confidence in the company's future, especially in the context of its ongoing clinical developments.

What Changed in the Firm's View

Ascendiant Capital raised its price target for OTLK from $10.00 to $10.00 while maintaining a Buy rating. This adjustment showcases the firm's optimism regarding the company’s pipeline and future growth prospects.

Analysts Set New Price Targets

In recent months, other analysts have also shown their support for OTLK. On September 11, 2026, Ascendiant Capital maintained its Buy rating but adjusted the target from $10.00 to $10.50. BTIG reiterated its Buy rating on August 14, 2026, with a target of $4.00, while HC Wainwright & Co. maintained a Neutral rating with a target of $1.60 on July 27, 2026. These varying opinions highlight the mixed sentiment among analysts, but overall, the trend seems favorable for OTLK.

Stock Performance and Relevance

As of the publication date, OTLK shares were trading at $1.11, significantly lower than the newly set price target of $10.00. The stock has fluctuated between a 52-week low of $0.16 and a high of $2.54, indicating a potential growth opportunity if the company meets its developmental goals.

12-month forecast

$OTLK price target

Outlook Therapeutics, Inc. daily closes and this analyst's $10 target. Not advice.

Recent Earnings

Outlook Therapeutics has faced challenges recently, reporting a negative earnings per share (EPS) of -0.70, and a revenue growth rate of -99.4%. The next earnings report is scheduled for December 18, 2026. Investors will be looking for signs of improvement as the company continues its clinical trials.

What OTLK Does

Outlook Therapeutics, based in Iselin, New Jersey, focuses on developing monoclonal antibodies for eye diseases. Its lead product candidate is ONS-5010, aimed at treating wet age-related macular degeneration. The reiteration of the Buy rating signifies the ongoing interest in the company’s innovations in the healthcare sector.

What to Watch at OTLK

Investors should stay tuned for the upcoming earnings report in December 2026, which will provide more insight into the company's financial health and the progress of its clinical trials. This reiteration from Ascendiant Capital reflects the firm’s ongoing support and confidence in Outlook Therapeutics, based on its past performance and future potential. Remember, the 13F filings only reflect historical positions as of the reporting period and may not represent current holdings.